NCT01357265View on ClinicalTrials.gov

Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

May 31, 2011

Study Completion Date

June 30, 2011

Conditions
Influenza
Interventions
BIOLOGICAL

Seasonal Influenza Vaccine

This phase II is performed as a multicenter study in adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .

Trial Locations (6)

16132

Dipartimento di Scienze della Salute Università di Genova, Via Pastore

20052

Dipartimento di malattie infettive Ospedale San Gerardo, Via Pergolesi 33

20127

Vaccine and Immunotherapy Research Center Department of Infectious and Tropical Diseases San Raffaele Scientific Institute, Via Stamira d'Ancona

66034

ASL Lanciano - Vasto,, Via S. Spaventa

66100

Dipartimento di Medicina e Scienze dell'Invecchiamento, Università G. D'Annunzio, Via Dei Vestini

Unknown

Distretto Sanitario di Base di Fossacesia, Via Polidoro-Vasto

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY

NCT01357265 - Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects | Biotech Hunter | Biotech Hunter